Navigation Links
Regeneron Reports Second Quarter 2011 Financial and Operating Results
Date:7/28/2011

TARRYTOWN, N.Y., July 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2011 and provided an update on development programs and upcoming milestones.  

Clinical Programs UpdateEYLEA™ (aflibercept injection)– Ophthalmologic DiseasesEYLEA™, also known as VEGF Trap-Eye, is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to EYLEA™ in the United States.  Bayer HealthCare LLC has rights to market EYLEA™ outside the U.S., where the companies will share equally in profits from any future sales of the product candidate.

In April 2011, the U.S. Food and Drug Administration (FDA) granted the Company's request for Priority Review of its Biologics License Application (BLA) for EYLEA™ for the treatment of the neovascular form of age-related macular degeneration (wet AMD) and set August 20, 2011 as the target date for an FDA decision. In June 2011, the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA unanimously recommended that the FDA approve EYLEA™.  

Also in June 2011, Bayer Healthcare submitted regulatory applications for marketing approval for EYLEA™ for the treatment of wet AMD in the European Union and in Japan.  As previously disclosed, Regeneron intends to submit an additional regulatory application for marketing approval for EYLEA™ in a second indication, central retinal vein occlusion (CRVO), in the U.S. in the second half of 2011, and Bayer HealthCare plans to submit a similar regulatory application in Europe in 2012.

During the second quarter of 2011, Regeneron and Bayer Healthcare each initiated a Phase 3 study of EYLEA™ in
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has ... services by test marketing a doctor note service to be made available to ... under $50 for each generated excuse, much less than the average daily pay ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Marietta dentists ... organ transplant issues. The doctors and staff ran a 5K race, the Iron ... Kimmerling DDS and Garrick McGrath DMD sponsored the event to help support projects with ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean ... by TripAdvisor earlier in 2015. The island of Providenciales itself received a TripAdvisor ... The Venetian on Grace Bay is offering a special promotion for newlyweds and honeymooners ...
(Date:8/30/2015)... ... 31, 2015 , ... Intellitec Solutions, based in Wilmington, DE, ... 5th & 6th in San Antonio, TX. Dedicated to bringing long term and ... all over the country come to share the latest and greatest in healthcare ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected to ... exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3
... Desmond Laurence, of the University of London says that ... that they compensated for any problem that // arises ... contracts that are badly worded and do not make ... British Medical Journal reported that accidental and unintentional injuries ...
... A retired doctor fond of gambling lost pounds 8million in a ... one is // that he is putting the blame on ... is suing for his money back. ,The name of ... drugs giant GlaxoSmithKline had failed to warn patients its medicine Requip ...
... health fraternity is deeply concerned. ,According to a ... full recovery from anorexia nervosa is slow, and women ... risk of death. ,As reported in International Journal ... the Klinik Roseneck Hospital for Behavioral Medicine in Prien, ...
... Centre scientists have unravelled mystery surrounding the leaf ... cancer in // animals. ,Anticancer Research journal ... treating mice with this extract before and after ... expression of a cell receptor associated with invasive ...
... found in Australia, could be used as mosquito repellents, in ... University of Adelaide gave mice the secretions of the dumpy ... minutes compared to 12 minutes for an untreated group, the ... the chemical that is used in commercial mosquito repellents, were ...
... garments that could do much more than just cover the ... // underwear that can smell like vanilla and stockings with ... that have been developed since the textile industry followed the ... with functional food. ,The garments have some additional ...
Cached Medicine News:Health News:Mystery unfolds about the Ginkgo biloba extract! 2Health News:Bio-Functional Garments That Could Revolutionize Fashion Industry 2Health News:Bio-Functional Garments That Could Revolutionize Fashion Industry 3
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Substrate Plasma for Factor II Assay by STA© Analyzers. Freeze-dried human serum and absorbed bovine plasma, the latter providing factor V and fibrinogen to the test system....
Substrate Plasma for Factor VIII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VIII has been removed by selective immuno-adsorption....
Medicine Products: